Latest MR-proADM News

April 2020

COVID-19 and scarce hospital resources: B·R·A·H·M·S MR-proADM for risk stratification to support decisions on the required level of care

The biomarker mid-regional proadrenomedullin (MR-proADM) allows an easier and more accurate risk assessment in pneumonia patients compared to standard clinical scores (e.g. SOFA), independent of etiology, i.e. viral, bacterial or combined infection. Thus, MR-proADM testing is a useful tool to improve early detection of organ dysfunction and progression to sepsis and septic shock. In conjunction with clinical evaluation and other laboratory findings, MR-proADM can be used as an aid to support decision on patient disposition.

COVID-19 and scarce hospital resources: B·R·A·H·M·S MR-proADM for risk stratification to support decisions on the required level of care >

 

News Archive

thermo scientific applied biosystems invitrogen fisher scientific unity lab service